BioLineRx Ltd. (BLRX)Healthcare | Biotechnology | Hevel Modi'in, Israel | NasdaqCM
2.60 USD
-0.25
(-8.772%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 2.60 |
Hot Take ↕ | Aug. 22, 2026, 2:56 a.m. EDT
The investment case here is structurally broken. Despite the company reporting positive clinical data and a massive 87% revenue surge, the stock has suffered a catastrophic 99% decline over the last nine years, with four consecutive years of negative returns ending recently. This multi-year trajectory is the market's definitive verdict that the business quality has deteriorated or that the previous valuation was a bubble, regardless of the latest headlines. Fundamentally, the company is burning cash with negative free cash flow and negative returns on equity, trading at a price significantly below its book value, which offers no margin of safety given the ongoing losses. There is no dividend to provide income, and the balance sheet is fragile. While the short-term chart shows a slight bounce off lows, the lack of analyst coverage and the heavy put positioning suggest that smart money is still betting against a recovery. The statistical forecast model is useless here due to low confidence, so we must rely on the hard reality of the fundamentals: a shrinking, losing business with no clear path to profitability yet. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.086505 |
| AutoETS | 0.086511 |
| MSTL | 0.112778 |
| AutoTheta | 0.164265 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 32% |
| H-stat | 12.45 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.240 |
| Excess Kurtosis | -0.81 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 43.533 |
| Revenue per Share | 0.6 |
| Market Cap | 11,357,567 |
| Trailing P/E | Infinity |
| Forward P/E | -4.06 |
| Beta | 0.71 |
| Website | https://www.biolinerx.com |
As of Aug. 22, 2026, 2:56 a.m. EDT: Speculators are positioning heavily for downside protection, evidenced by significant open interest in out-of-the-money puts at strikes below the current price ($2.00 and $1.00) relative to call volume. While there is some call activity at lower strikes ($1.00-$3.00), the overwhelming open interest concentration in the $5.00 strike for November and February expirations suggests a speculative bet on a continued decline or a failed rally, rather than a bullish breakout. Implied volatility is elevated for near-term expiration, indicating fear of a sharp drop.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.264 |
| Address1 | Modi’in Technology Park |
| Address2 | 2 HaMa’ayan Street |
| All Time High | 4,122.0 |
| All Time Low | 2.15 |
| Ask | 2.31 |
| Ask Size | 1 |
| Average Daily Volume10 Day | 7,990 |
| Average Daily Volume3 Month | 16,022 |
| Average Volume | 16,022 |
| Average Volume10Days | 7,990 |
| Beta | 0.711 |
| Bid | 2.2 |
| Bid Size | 1 |
| Book Value | 3.6 |
| City | Hevel Modi'in |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | Israel |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 2.6 |
| Current Ratio | 1.584 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 2.72 |
| Day Low | 2.56 |
| Debt To Equity | 43.533 |
| Dividend Date | 1,563,148,800 |
| Earnings Call Timestamp End | 1,788,206,400 |
| Earnings Call Timestamp Start | 1,788,206,400 |
| Earnings Timestamp | 1,788,179,400 |
| Earnings Timestamp End | 1,788,179,400 |
| Earnings Timestamp Start | 1,788,179,400 |
| Ebitda | -10,750,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -0.669 |
| Enterprise To Revenue | 5.13 |
| Enterprise Value | 7,192,529 |
| Eps Forward | -0.64 |
| Eps Trailing Twelve Months | 0.0 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 972 8 642 9101 |
| Fifty Day Average | 2.9238 |
| Fifty Day Average Change | -0.3238001 |
| Fifty Day Average Change Percent | -0.11074632 |
| Fifty Two Week Change Percent | -26.4 |
| Fifty Two Week High | 4.56 |
| Fifty Two Week High Change | -1.96 |
| Fifty Two Week High Change Percent | -0.42982456 |
| Fifty Two Week Low | 2.15 |
| Fifty Two Week Low Change | 0.4499998 |
| Fifty Two Week Low Change Percent | 0.20930223 |
| Fifty Two Week Range | 2.15 - 4.56 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,311,773,400,000 |
| Float Shares | 4,090,667 |
| Forward Eps | -0.64 |
| Forward P E | -4.0625 |
| Free Cashflow | -5,490,125 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 20 |
| Fullday Change | -0.25 |
| Fullday Change Percent | -8.77193 |
| Fullday Price | 2.6 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.79244006 |
| Gross Profits | 1,111,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.03908 |
| Held Percent Institutions | 0.015240001 |
| Implied Shares Outstanding | 4,368,295 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,738,195,200 |
| Last Split Factor | 1:40 |
| Long Business Summary | BioLineRx Ltd., a biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes GLIX1, an oral, small molecule targeting DNA damage response in glioblastoma and other cancers; and APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel. |
| Long Name | BioLineRx Ltd. |
| Market | us_market |
| Market Cap | 11,357,567 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_5015080 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -7,903,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 13,191,731 |
| Number Of Analyst Opinions | 1 |
| Open | 2.56 |
| Operating Cashflow | -7,763,000 |
| Operating Margins | -6.29769 |
| Payout Ratio | 0.0 |
| Phone | 972 8 642 9100 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 2.6 |
| Post Market Time | 1,787,961,351 |
| Previous Close | 2.85 |
| Price Hint | 4 |
| Price To Book | 0.7222222 |
| Price To Sales Trailing12 Months | 8.100975 |
| Profit Margins | 0.0 |
| Quick Ratio | 1.413 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.25 |
| Regular Market Change Percent | -8.77193 |
| Regular Market Day High | 2.72 |
| Regular Market Day Low | 2.56 |
| Regular Market Day Range | 2.56 - 2.72 |
| Regular Market Open | 2.56 |
| Regular Market Previous Close | 2.85 |
| Regular Market Price | 2.6 |
| Regular Market Time | 1,787,947,200 |
| Regular Market Volume | 47,837 |
| Return On Assets | -0.16554001 |
| Return On Equity | -0.46723 |
| Revenue Growth | 0.871 |
| Revenue Per Share | 0.6 |
| Sand P52 Week Change | 0.20504117 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 4,368,295 |
| Shares Percent Shares Out | 0.0308 |
| Shares Short | 134,579 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 145,926 |
| Short Name | BioLineRx Ltd. |
| Short Percent Of Float | 0.0309 |
| Short Ratio | 15.72 |
| Source Interval | 15 |
| Symbol | BLRX |
| Target High Price | 23.0 |
| Target Low Price | 23.0 |
| Target Mean Price | 23.0 |
| Target Median Price | 23.0 |
| Total Cash | 17,353,000 |
| Total Cash Per Share | 3.988 |
| Total Debt | 9,070,000 |
| Total Revenue | 1,402,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | 0.0 |
| Trailing P E | Infinity |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 2.9212 |
| Two Hundred Day Average Change | -0.32120013 |
| Two Hundred Day Average Change Percent | -0.10995486 |
| Type Disp | Equity |
| Volume | 47,837 |
| Website | https://www.biolinerx.com |
| Zip | 7,177,871 |